Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01572948 · ClinicalTrials.gov registry record · NA
A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)
A NA study of COPD, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT01572948: Completed NA study of COPD, sponsored by University of Alabama at Birmingham.
NCT01572948 is a NA study of COPD that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 27 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01572948, a NA study of COPD, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to propose that roflumilast is associated with meaningful reductions in biomarkers of pulmonary inflammation and sputum neutrophilia, including confirmation of previously described results, and correlate these findings with improvement in pulmonary function, sputum scores, and quality of life in stable moderate to severe COPD. The investigators aim to demonstrate this regardless of concomitant medication use, including inhaled corticosteroids. Additionally, the investigators hope to provide a mechanistic pathway by which these effects occur.
Conditions Studied
Interventions
- DRUG placebo
- DRUG roflumilast
Study Locations (1)
Alabama
- UAB Lung Health Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-06 |
| Phase | NA |
What the finished NCT01572948 record still lists
NCT01572948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01572948 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT01572948 about?
NCT01572948 is a clinical study titled "A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)". The purpose of the study is to propose that roflumilast is associated with meaningful reductions in biomarkers of pulmonary inflammation and sputum neutrophilia, including confirmation of previously described results, and correlate these findings with improvement in pulmonary function, sputum scores...
What is the current status of trial NCT01572948?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2012-06. Estimated completion is 2014-06.
What conditions does trial NCT01572948 study?
This clinical trial studies the following conditions: COPD.
What interventions are being tested in trial NCT01572948?
The interventions under investigation include: placebo (DRUG), roflumilast (DRUG).
Who is sponsoring clinical trial NCT01572948?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01572948 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01572948's enrollment target sits among peer trials
27 72nd of 85 higher than 14 of 85 other COPD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
The Reducing REVISITS Study: A Cluster RCT
RECRUITING · NA
-
The Effect of a Technology-Mediated Integrated Walking and Tai Chi Intervention on Physical Function in Veterans With COPD and Chronic Musculoskeletal Pain
RECRUITING · NA
-
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia